Vericiguat: All-Cause Mortality Benefit Claimed in Heart Failure
Vericiguat for Heart Failure: A New Option, But Is It Ready for Prime Time?
Table of Contents
Understanding Heart Failure with Reduced Ejection Fraction (HFrEF)
Heart failure is a complex condition where the heart can’t pump enough blood to meet the body’s needs. HFrEF,specifically,means the heart muscle is weakened and can’t contract effectively,resulting in a reduced ejection fraction – the percentage of blood pumped out with each beat. This is a serious condition, affecting millions worldwide and leading to frequent hospitalizations and a diminished quality of life.
Current standard of care for HFrEF includes medications like ACE inhibitors or arbs, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors. Despite these advancements, a significant number of patients continue to experience symptoms and adverse events, highlighting the need for additional therapeutic options.
How Vericiguat Works: A Novel mechanism
Vericiguat represents a different approach to treating HFrEF. It’s a soluble guanylate cyclase (sGC) stimulator. sGC is an enzyme that plays a crucial role in relaxing blood vessels and improving blood flow. in HFrEF, sGC activity is often reduced. Vericiguat directly stimulates sGC, even in the presence of low nitric oxide levels, leading to vasodilation and possibly reducing the workload on the heart.
This mechanism differs from existing HFrEF therapies, which primarily target neurohormonal activation or directly improve heart muscle contractility. Theoretically, this novel approach could offer benefits for patients who haven’t responded adequately to conventional treatments.
The VICTORIA Trial: Examining the Evidence
The primary evidence supporting vericiguat comes from the VICTORIA (VERICIGUAT CV outcomes Trial),a large,randomized,double-blind,placebo-controlled trial. The study enrolled over 5,000 patients with symptomatic hfref who had recently experienced a worsening heart failure event (hospitalization or need for intravenous diuretics). All participants were already receiving guideline-directed medical therapy.
The primary outcome was a composite of cardiovascular death or first hospitalization for heart failure. Results showed that vericiguat reduced the risk of this composite outcome by 10% compared to placebo. Specifically, there was a statistically significant reduction in all-cause mortality, with a hazard ratio of 0.90 (95% confidence interval, 0.82-0.99). There was also a trend towards fewer heart failure hospitalizations, although this did not reach statistical significance.
| Outcome | Vericiguat (HR) | P-value |
|---|---|---|
| Cardiovascular Death or HF Hospitalization | 0.90 | 0.02 |
| All-Cause Mortality | 0.90 | 0.02 |
| Heart Failure Hospitalization | 0 |